TY - GEN
T1 - Design and synthesis of free fatty acid receptor modulators
AU - Hansen, Anders Højgaard
PY - 2017
Y1 - 2017
N2 - Evidence suggests that the short-chain free fatty acid receptors FFA2 and FFA3 are involved in
regulation of metabolism and inflammatory responses, and as such these receptors represent potential
drug targets for treatment of type 2 diabetes, obesity, and inflammatory diseases.Inspired by a pyrrolidine-based agonist, Manuscript I and Chapter 2 describe the discovery of a potent
and selective thiazolidine-based agonist with optimal lipophilic ligand efficiency. Attempts at replacing
the thiazolidine with other scaffolds were realized, and one weakly potent agonist identified. Chapter 2
also describes the synthesis of a known FFA2 agonist, which was used as a tool for studying FFA2-
mediated responses in neutrophils, as described in detail within Publication IV.Chapter 3 describes the use of an alternative synthetic route to produce a β-amino acid building block
central for synthesis of Euroscreen-type FFA2 antagonists. The second part presents scaffold
simplification strategies, which led to the discovery of a new reasonably potent antagonist for FFA2.
The last section describes the synthesis of a known azetidine-based FFA2 antagonist, whose effect on
eosinophils is currently being investigated by our collaborators.First part of Chapter 4 reports on the design, synthesis and application of the first potent FFA2
fluorescent tracer. Second part of Chapter 4 presents the design and synthesis of a reasonably potent
photoswitchable agonist for FFA2.Chapter 5 outlines selected parts of the work covered in Publication I. Based on the FFA1 crystal
structure, a homology model of FFA2 was generated and applied for molecular docking experiments,
which to some extent were able to rationalize binding data obtained using a radioactive FFA2
antagonist. Second part of Chapter 2 covers work conducted during my exchange stay at Queen’s
University, Belfast in the group of Dr. Irina Tikhonova. An FFA2 homology model was used for
structure-based virtual screening of commercial compound libraries. A selection of hits was purchased
and tested in biological assays; unfortunately no active compounds were retrieved.Chapter 6 covers parts of Publication III along with unpublished results. It reports on synthesis and
pharmacological characterization of FFA3 allosteric modulators. Chapter 7 and Manuscript II
describe a synthetic methodology where oxalyl chloride is employed as a convenient carbon monoxide
source for practical alkoxycarbonylation of aryl bromides.
AB - Evidence suggests that the short-chain free fatty acid receptors FFA2 and FFA3 are involved in
regulation of metabolism and inflammatory responses, and as such these receptors represent potential
drug targets for treatment of type 2 diabetes, obesity, and inflammatory diseases.Inspired by a pyrrolidine-based agonist, Manuscript I and Chapter 2 describe the discovery of a potent
and selective thiazolidine-based agonist with optimal lipophilic ligand efficiency. Attempts at replacing
the thiazolidine with other scaffolds were realized, and one weakly potent agonist identified. Chapter 2
also describes the synthesis of a known FFA2 agonist, which was used as a tool for studying FFA2-
mediated responses in neutrophils, as described in detail within Publication IV.Chapter 3 describes the use of an alternative synthetic route to produce a β-amino acid building block
central for synthesis of Euroscreen-type FFA2 antagonists. The second part presents scaffold
simplification strategies, which led to the discovery of a new reasonably potent antagonist for FFA2.
The last section describes the synthesis of a known azetidine-based FFA2 antagonist, whose effect on
eosinophils is currently being investigated by our collaborators.First part of Chapter 4 reports on the design, synthesis and application of the first potent FFA2
fluorescent tracer. Second part of Chapter 4 presents the design and synthesis of a reasonably potent
photoswitchable agonist for FFA2.Chapter 5 outlines selected parts of the work covered in Publication I. Based on the FFA1 crystal
structure, a homology model of FFA2 was generated and applied for molecular docking experiments,
which to some extent were able to rationalize binding data obtained using a radioactive FFA2
antagonist. Second part of Chapter 2 covers work conducted during my exchange stay at Queen’s
University, Belfast in the group of Dr. Irina Tikhonova. An FFA2 homology model was used for
structure-based virtual screening of commercial compound libraries. A selection of hits was purchased
and tested in biological assays; unfortunately no active compounds were retrieved.Chapter 6 covers parts of Publication III along with unpublished results. It reports on synthesis and
pharmacological characterization of FFA3 allosteric modulators. Chapter 7 and Manuscript II
describe a synthetic methodology where oxalyl chloride is employed as a convenient carbon monoxide
source for practical alkoxycarbonylation of aryl bromides.
M3 - Ph.D. thesis
PB - Syddansk Universitet. Det Naturvidenskabelige Fakultet
CY - Odense
ER -